國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance to ibritumomab in lymphoma

Chatal, Jean-Francois.

Resistance to ibritumomab in lymphoma

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance to ibritumomab in lymphomaedited by Makoto Hosono, Jean-Francois Chatal.
其他作者:	Hosono, Makoto.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	xiii, 158 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	LymphomasTreatment.
電子資源:	http://dx.doi.org/10.1007/978-3-319-78238-6
ISBN:	9783319782386$q(electronic bk.)

Resistance to ibritumomab in lymphoma
Resistance to ibritumomab in lymphoma[electronic resource] /edited by Makoto Hosono, Jean-Francois Chatal. - Cham :Springer International Publishing :2018. - xiii, 158 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.182196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

ISBN: 9783319782386$q(electronic bk.)

Standard No.: 10.1007/978-3-319-78238-6doiSubjects--Topical Terms:

520176
Lymphomas
--Treatment.

LC Class. No.: RC280.L9 / R475 2018

Dewey Class. No.: 616.99446

Resistance to ibritumomab in lymphoma
LDR:01953nmm a2200325 a 4500 001 537598
003 DE-He213
005 20181105143639.0
006 m d
007 cr nn 008maaau
008 190116s2018 gw s 0 eng d
020 $a 9783319782386$q(electronic bk.)
020 $a 9783319782379$q(paper)
024 7 $a 10.1007/978-3-319-78238-6 $2 doi
035 $a 978-3-319-78238-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L9 $b R475 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99446 $2 23
090 $a RC280.L9 $b R433 2018
245 0 0 $a Resistance to ibritumomab in lymphoma $h [electronic resource] / $c edited by Makoto Hosono, Jean-Francois Chatal.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xiii, 158 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.18
505 0 $a Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
520 $a This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
650 0 $a Lymphomas $x Treatment. $3 520176
650 0 $a Drug resistance in cancer cells. $3 281104
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Cancer Research. $3 273660
700 1 $a Hosono, Makoto. $3 814631
700 1 $a Chatal, Jean-Francois. $3 814632
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 711051
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-78238-6
950 $a Biomedical and Life Sciences (Springer-11642)